Antibody Drug Conjugates Global Market Opportunities And Strategies To 2033

Description

Antibody drug conjugates (ADCs) refer to a class of biopharmaceutical drugs designed as a targeted therapy for treating cancer. An ADC is a complex molecule that consists of an antibody linked to a biologically active drug or toxin, designed to selectively target and kill cancer cells while sparing healthy tissue.

The antibody drug conjugates market consists of sales, by entities (such as organizations, sole traders or partnerships), of antibody drug conjugates that are utilized when precision in targeting cancer cells is critical, often after other treatments have failed or in combination with other therapies to enhance efficacy. They are designed to selectively deliver chemotherapy agents to cancer cells while minimizing damage to healthy cells.

The global antibody drug conjugates market was valued at $1,847.94 million in 2018 which grew till 2023 at a compound annual growth rate (CAGR) of more than 41.00%.

Supportive Policies And Faster Approval Processes

Supportive policies and faster approval processes propelled the growth of the antibody drug conjugates market. Supportive regulatory policies accelerate the development and approval of innovative therapies such as antibody-drug conjugates (ADCs) for critical conditions such as cancer. Expedited pathways like accelerated approval and breakthrough therapy designation streamline the approval process, granting earlier access to ADCs for patients. This swift approval process ensures the timely delivery of potentially life-saving treatments to those in need. For instance, in March 2023, the Food and Drug Administration (FDA), a US-based federal agency responsible for protecting public health, released draft guidance outlining clinical trial considerations for accelerated approval applications of oncology therapeutics. This pathway, commonly utilized for oncology drugs due to the urgency of cancer treatment, offers patients early access to innovative therapies. The guidance aims to assist sponsors in designing trials that support accelerated approval, emphasizing the importance of efficient and high-quality trial design in maximizing benefits for cancer patients. Therefore, supportive policies and faster approval processes supported the growth of the antibody drug conjugates market during the historic period.

Strategic Partnerships And Collaborations Among Market Players

Major companies operating in the antibody drug conjugates market are pursuing strategic partnerships to provide comprehensive solutions and advance their capabilities. Strategic partnerships enable companies to leverage each other's strengths and resources to achieve mutual benefits and success. For example, in July 2023, BeiGene Ltd., a US-based biotechnology company, partnered with Duality Biologics, a China-based clinical-stage company. With this partnership, they aim to develop and commercialize a preclinical antibody-drug conjugate (ADC) therapy for patients with select solid tumors. The strengths of both companies will accelerate the development and commercialization of this promising ADC therapy. Further, in March 2022, Sanofi, a France-based multinational pharmaceutical and healthcare company, collaborated with a US-based biotechnology company, Seagen Inc., to create antibody-drug conjugates (ADCs) for up to three cancer targets , develop and market them. The collaboration would make use of the exclusive monoclonal antibody (mAb) technology from Sanofi and the exclusive ADC technology from Seagen. Through this cooperation, candidate medications with the potential to give cancer patients and their families fresh hope would be created via the synergistic combination of molecules and platforms.

The global antibody drug conjugates market is highly concentrated, with large players dominating the market. The top ten competitors in the market made up to 99.26% of the total market in 2022.

Antibody Drug Conjugates Global Market Opportunities And Strategies To 2033 from The Business Research Company provides the strategists; marketers and senior management with the critical information they need to assess the global antibody drug conjugates market as it emerges from the COVID-19 shut down.

Reasons to Purchase

Gain a truly global perspective with the most comprehensive report available on this market covering 15 geographies.
Understand how the market is being affected by the coronavirus and how it is likely to emerge and grow as the impact of the virus abates.
Create regional and country strategies on the basis of local data and analysis.
Identify growth segments for investment.
Outperform competitors using forecast data and the drivers and trends shaping the market.
Understand customers based on the latest market research findings.
Benchmark performance against key competitors.
Utilize the relationships between key data sets for superior strategizing.
Suitable for supporting your internal and external presentations with reliable high-quality data and analysis.

Where is the largest and fastest-growing market for antibody drug conjugates? How does the market relate to the overall economy; demography and other similar markets? What forces will shape the market going forward? The antibody drug conjugates market global report from The Business Research Company answers all these questions and many more.

The report covers market characteristics; size and growth; segmentation; regional and country breakdowns; competitive landscape; market shares; trends and strategies for this market. It traces the market's history and forecasts market growth by geography. It places the market within the context of the wider antibody drug conjugates market; and compares it with other markets.

The report covers the following chapters

Introduction and Market Characteristics- Brief introduction to the segmentations covered in the market, definitions and explanations about the segment by linker type, by product, by application and by end-user.
Key Trends- Highlights the major trends shaping the global market. This section also highlights likely future developments in the market.
Macro-Economic Scenario- The report provides an analysis of the impact of the COVID-19 pandemic, impact of the Russia-Ukraine war and impact of rising inflation on global and regional markets, providing strategic insights for businesses in the antibody drug conjugates market.
Global Market Size And Growth- Global historic (2018-2023) and forecast (2023-2028, 2033F) market values and drivers and restraints that support and control the growth of the market in the historic and forecast periods.
Regional And Country Analysis- Historic (2018-2023) and forecast (2023-2028, 2033F) market values and growth and market share comparison by region and country.
Market Segmentation- Contains the market values (2018-2023) (2023-2028, 2033F) and analysis for each segment by linker type, by product, by application and by end-user in the market. Historic (2018-2023) and forecast (2023-2028) and (2028-2033) market values and growth and market share comparison by region market.
Regional Market Size and Growth- Regional market size (2023), historic (2018-2023) and forecast (2023-2028, 2033F) market values and growth and market share comparison of countries within the region. This report includes information on all the regions Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East and Africa and major countries within each region.
Competitive Landscape- Details on the competitive landscape of the market, estimated market shares and company profiles of the leading players.
Other Major And Innovative Companies Details on the company profiles of other major and innovative companies in the market.
Competitive Benchmarking- Briefs on the financials comparison between major players in the market.
Competitive Dashboard- Briefs on competitive dashboard of major players.
Key Mergers and Acquisitions- Information on recent mergers and acquisitions in the market is covered in the report. This section gives key financial details of mergers and acquisitions which have shaped the market in recent years.
Market Opportunities And Strategies- Describes market opportunities and strategies based on findings of the research, with information on growth opportunities across countries, segments and strategies to be followed in those markets.
Conclusions And Recommendations- This section includes recommendations for antibody drug conjugates providers in terms of product/service offerings geographic expansion, marketing strategies and target groups.
Appendix- This section includes details on the NAICS codes covered, abbreviations and currencies codes used in this report.

Markets Covered:

1) By Linker Type: Cleavable Linker; Non-Cleavable Linker
2) By Product: Kadcyla; Enhertu; Adcetris; Polivy; Trodelvy; Padcev; Other Products
3) By Application: Hematopoietic Cancers; Breast Cancer; Ovarian Cancer; Lung Cancer; Brain Tumor; Other Applications
4) By End User: Hospital; Clinics; Specialty Centers; Other End Users
Companies Mentioned: F. Hoffmann-La Roche Ltd.; Daiichi Sankyo Company Limited; Seagen Inc.; Gilead Sciences Inc.; Genmab
Countries: China; Australia; India; Indonesia; Japan; South Korea; USA; Canada; Brazil; France; Germany; Italy; Spain; UK; Russia
Regions: Asia-Pacific; Western Europe; Eastern Europe; North America; South America; Middle East; Africa
Time-series: Five years historic and ten years forecast.
Data: Ratios of market size and growth to related markets; GDP proportions; expenditure per capita; antibody drug conjugates indicators comparison.
Data segmentations: country and regional historic and forecast data; market share of competitors; market segments.
Sourcing and Referencing: Data and analysis throughout the report is sourced using end notes.

Product Code: o&s1259

1 Executive Summary

1.1 Antibody Drug Conjugates - Market Attractiveness And Macro economic Landscape

2 Table Of Contents

3 List Of Tables

4 List Of Figures

5 Report Structure

6 Market Characteristics

6.1 General Market Definition
6.2 Summary
6.3 Antibody Drug Conjugates Market Definition And Segmentations
6.4 Market Segmentation By Linked Type
- 6.4.1 Cleavable Linker
- 6.4.2 Non-cleavable Linker
6.5 Market Segmentation By Product
- 6.5.1 Adcetris
- 6.5.2 Kadcyla
- 6.5.3 Enhertu
- 6.5.4 Polivy
- 6.5.5 Trodelvy
- 6.5.6 Padcev
- 6.5.7 Other Products
6.6 Market Segmentation By Application
- 6.6.1 Hematopoietic Cancers
- 6.6.2 Breast Cancer
- 6.6.3 Lung Cancer
- 6.6.4 Brain Tumor
- 6.6.5 Ovarian Cancer
- 6.6.6 Other Applications
6.7 Market Segmentation By End User
- 6.7.1 Hospitals And Clinics
- 6.7.2 Specialty Centers
- 6.7.3 Other End-Users

7 Major Market Trends

7.1 Strategic Partnerships And Collaborations Among Market Players
7.2 Significant Investments In R&D By Market Players
7.3 Focus On New mAb Targets For ADCs Development

8 Antibody Drug Conjugates Market - Macro Economic Scenario

8.1 COVID-19 Impact On The Antibody Drug Conjugates Market
8.2 Impact Of The War In Ukraine On The Antibody Drug Conjugates Market
8.3 Impact Of High Inflation On The Antibody Drug Conjugates Market

9 Global Market Size and Growth

9.1 Market Size
9.2 Historic Market Growth, 2018 - 2023, Value ($ Million)
- 9.2.1 Market Drivers 2018 - 2023
- 9.2.2 Market Restraints 2018 - 2023
9.3 Forecast Market Growth, 2023 - 2028, 2033F Value ($ Million)
- 9.3.1 Market Drivers 2023 - 2028
- 9.3.2 Market Restraints 2023 - 2028

10 Global Antibody Drug Conjugates Market Segmentation

10.1 Global Antibody Drug Conjugates Market, Segmentation By Linker Type, Historic And Forecast, 2018 - 2023, 2028F, 2033F, Value ($ Million)
10.2 Global Antibody Drug Conjugates Market, Segmentation By Application, Historic And Forecast, 2018 - 2023, 2028F, 2033F, Value ($ Million)
10.3 Global Antibody Drug Conjugates Market, Segmentation By End User, Historic And Forecast, 2018 - 2023, 2028F, 2033F, Value ($ Million)
10.4 Global Antibody Drug Conjugates Market, Segmentation By Product, Historic And Forecast, 2018 - 2023, 2028F, 2033F, Value ($ Million)

11 Antibody Drug Conjugates Market, Regional and Country Analysis

11.1 Global Antibody Drug Conjugates Market, By Region, Historic and Forecast, 2018 - 2023, 2028F, 2033F, Value ($ Million)
11.2 Global Antibody Drug Conjugates Market, By Country, Historic and Forecast, 2018 - 2023, 2028F, 2033F, Value ($ Million)

12 Asia-Pacific Market

12.1 Summary
12.2 Market Overview
- 12.2.1 Region Information
- 12.2.2 Market Information
- 12.2.3 Background Information
- 12.2.4 Government Initiatives
- 12.2.5 Regulations
- 12.2.6 Regulatory Bodies
- 12.2.7 Major Associations
- 12.2.8 Taxes Levied
- 12.2.9 Corporate Tax Structure
- 12.2.10 Investments
- 12.2.11 Major Companies
12.3 Asia-Pacific Antibody Drug Conjugates Market, Segmentation By Linker Type, Historic And Forecast, 2018 - 2023, 2028F, 2033F, Value ($ Million)
12.4 Asia-Pacific Antibody Drug Conjugates Market, Segmentation By Application, Historic And Forecast, 2018 - 2023, 2028F, 2033F, Value ($ Million)
12.5 Asia-Pacific Antibody Drug Conjugates Market, Segmentation By End User, Historic And Forecast, 2018 - 2023, 2028F, 2033F, Value ($ Million)
12.6 Asia-Pacific Antibody Drug Conjugates Market: Country Analysis
12.7 China Market
12.8 Summary
12.9 Market Overview
- 12.9.1 Country Information
- 12.9.2 Market Information
- 12.9.3 Background Information
- 12.9.4 Government Initiatives
- 12.9.5 Regulations
- 12.9.6 Regulatory Bodies
- 12.9.7 Major Associations
- 12.9.8 Taxes Levied
- 12.9.9 Corporate Tax Structure
- 12.9.10 Investments
- 12.9.11 Major Companies
12.10 China Antibody Drug Conjugates Market, Segmentation By Linker Type, Historic And Forecast, 2018 - 2023, 2028F, 2033F, Value ($ Million)
12.11 China Antibody Drug Conjugates Market, Segmentation By Application, Historic And Forecast, 2018 - 2023, 2028F, 2033F, Value ($ Million)
12.12 China Antibody Drug Conjugates Market, Segmentation By End User, Historic And Forecast, 2018 - 2023, 2028F, 2033F, Value ($ Million)
12.13 India Market
12.14 India Antibody Drug Conjugates Market, Segmentation By Linker Type, Historic And Forecast, 2018 - 2023, 2028F, 2033F, Value ($ Million)
12.15 India Antibody Drug Conjugates Market, Segmentation By Application, Historic And Forecast, 2018 - 2023, 2028F, 2033F, Value ($ Million)
12.16 India Antibody Drug Conjugates Market, Segmentation By End User, Historic And Forecast, 2018 - 2023, 2028F, 2033F, Value ($ Million)
12.17 Japan Market
12.18 Japan Antibody Drug Conjugates Market, Segmentation By Linker Type, Historic And Forecast, 2018 - 2023, 2028F, 2033F, Value ($ Million)
12.19 Japan Antibody Drug Conjugates Market, Segmentation By Application, Historic And Forecast, 2018 - 2023, 2028F, 2033F, Value ($ Million)
12.20 Japan Antibody Drug Conjugates Market, Segmentation By End User, Historic And Forecast, 2018 - 2023, 2028F, 2033F, Value ($ Million)
12.21 Australia Market
12.22 Australia Antibody Drug Conjugates Market, Segmentation By Linker Type, Historic And Forecast, 2018 - 2023, 2028F, 2033F, Value ($ Million)
12.23 Australia Antibody Drug Conjugates Market, Segmentation By Application, Historic And Forecast, 2018 - 2023, 2028F, 2033F, Value ($ Million)
12.24 Australia Antibody Drug Conjugates Market, Segmentation By End User, Historic And Forecast, 2018 - 2023, 2028F, 2033F, Value ($ Million)
12.25 Indonesia Market
12.26 Indonesia Antibody Drug Conjugates Market, Segmentation By Linker Type, Historic And Forecast, 2018 - 2023, 2028F, 2033F, Value ($ Million)
12.27 Indonesia Antibody Drug Conjugates Market, Segmentation By Application, Historic And Forecast, 2018 - 2023, 2028F, 2033F, Value ($ Million)
12.28 Indonesia Antibody Drug Conjugates Market, Segmentation By End User, Historic And Forecast, 2018 - 2023, 2028F, 2033F, Value ($ Million)
12.29 South Korea Market
12.30 South Korea Antibody Drug Conjugates Market, Segmentation By Linker Type, Historic And Forecast, 2018 - 2023, 2028F, 2033F, Value ($ Million)
12.31 South Korea Antibody Drug Conjugates Market, Segmentation By Application, Historic And Forecast, 2018 - 2023, 2028F, 2033F, Value ($ Million)
12.32 South Korea Antibody Drug Conjugates Market, Segmentation By End User, Historic And Forecast, 2018 - 2023, 2028F, 2033F, Value ($ Million)

13 Western Europe Market

13.1 Summary
13.2 Market Overview
- 13.2.1 Region Information
- 13.2.2 Market Information
- 13.2.3 Background Information
- 13.2.4 Government Initiatives
- 13.2.5 Regulations
- 13.2.6 Regulatory Bodies
- 13.2.7 Major Associations
- 13.2.8 Taxes Levied
- 13.2.9 Corporate Tax Structure
- 13.2.10 Investments
- 13.2.11 Major Companies
13.3 Western Europe Antibody Drug Conjugates Market, Segmentation By Linker Type, Historic And Forecast, 2018 - 2023, 2028F, 2033F, Value ($ Million)
13.4 Western Europe Antibody Drug Conjugates Market, Segmentation By Application, Historic And Forecast, 2018 - 2023, 2028F, 2033F, Value ($ Million)
13.5 Western Europe Antibody Drug Conjugates Market, Segmentation By End User, Historic And Forecast, 2018 - 2023, 2028F, 2033F, Value ($ Million)
13.6 Western Europe Antibody Drug Conjugates Market: Country Analysis
13.7 UK Market
13.8 UK Antibody Drug Conjugates Market, Segmentation By Linker Type, Historic And Forecast, 2018 - 2023, 2028F, 2033F, Value ($ Million)
13.9 UK Antibody Drug Conjugates Market, Segmentation By Application, Historic And Forecast, 2018 - 2023, 2028F, 2033F, Value ($ Million)
13.10 UK Antibody Drug Conjugates Market, Segmentation By End User, Historic And Forecast, 2018 - 2023, 2028F, 2033F, Value ($ Million)
13.11 Germany Market
13.12 Germany Antibody Drug Conjugates Market, Segmentation By Linker Type, Historic And Forecast, 2018 - 2023, 2028F, 2033F, Value ($ Million)
13.13 Germany Antibody Drug Conjugates Market, Segmentation By Application, Historic And Forecast, 2018 - 2023, 2028F, 2033F, Value ($ Million)
13.14 Germany Antibody Drug Conjugates Market, Segmentation By End User, Historic And Forecast, 2018 - 2023, 2028F, 2033F, Value ($ Million)
13.15 France Market
13.16 France Antibody Drug Conjugates Market, Segmentation By Linker Type, Historic And Forecast, 2018 - 2023, 2028F, 2033F, Value ($ Million)
13.17 France Antibody Drug Conjugates Market, Segmentation By Application, Historic And Forecast, 2018 - 2023, 2028F, 2033F, Value ($ Million)
13.18 France Antibody Drug Conjugates Market, Segmentation By End User, Historic And Forecast, 2018 - 2023, 2028F, 2033F, Value ($ Million)
13.19 Italy Market
13.20 Italy Antibody Drug Conjugates Market, Segmentation By Linker Type, Historic And Forecast, 2018 - 2023, 2028F, 2033F, Value ($ Million)
13.21 Italy Antibody Drug Conjugates Market, Segmentation By Application, Historic And Forecast, 2018 - 2023, 2028F, 2033F, Value ($ Million)
13.22 Italy Antibody Drug Conjugates Market, Segmentation By End User, Historic And Forecast, 2018 - 2023, 2028F, 2033F, Value ($ Million)
13.23 Spain Market
13.24 Spain Antibody Drug Conjugates Market, Segmentation By Linker Type, Historic And Forecast, 2018 - 2023, 2028F, 2033F, Value ($ Million)
13.25 Spain Antibody Drug Conjugates Market, Segmentation By Application, Historic And Forecast, 2018 - 2023, 2028F, 2033F, Value ($ Million)
13.26 Spain Antibody Drug Conjugates Market, Segmentation By End User, Historic And Forecast, 2018 - 2023, 2028F, 2033F, Value ($ Million)

14 Eastern Europe Market

14.1 Summary
14.2 Market Overview
- 14.2.1 Region Information
- 14.2.2 Market Information
- 14.2.3 Background Information
- 14.2.4 Government Initiatives
- 14.2.5 Regulations
- 14.2.6 Regulatory Bodies
- 14.2.7 Major Associations
- 14.2.8 Taxes Levied
- 14.2.9 Corporate Tax Structure
- 14.2.10 Investments
- 14.2.11 Major Companies
14.3 Eastern Europe Antibody Drug Conjugates Market, Segmentation By Linker Type, Historic And Forecast, 2018 - 2023, 2028F, 2033F, Value ($ Million)
14.4 Eastern Europe Antibody Drug Conjugates Market, Segmentation By Application, Historic And Forecast, 2018 - 2023, 2028F, 2033F, Value ($ Million)
14.5 Eastern Europe Antibody Drug Conjugates Market, Segmentation By End User, Historic And Forecast, 2018 - 2023, 2028F, 2033F, Value ($ Million)
14.6 Eastern Europe Antibody Drug Conjugates Market: Country Analysis
14.7 Russia Market
14.8 Russia Antibody Drug Conjugates Market, Segmentation By Linker Type, Historic And Forecast, 2018 - 2023, 2028F, 2033F, Value ($ Million)
14.9 Russia Antibody Drug Conjugates Market, Segmentation By Application, Historic And Forecast, 2018 - 2023, 2028F, 2033F, Value ($ Million)
14.10 Russia Antibody Drug Conjugates Market, Segmentation By End User, Historic And Forecast, 2018 - 2023, 2028F, 2033F, Value ($ Million)

15 North America Market

15.1 Summary
15.2 Market Overview
- 15.2.1 Region Information
- 15.2.2 Market Information
- 15.2.3 Background Information
- 15.2.4 Government Initiatives
- 15.2.5 Regulations
- 15.2.6 Regulatory Bodies
- 15.2.7 Major Associations
- 15.2.8 Taxes Levied
- 15.2.9 Corporate Tax Structure
- 15.2.10 Investments
- 15.2.11 Major Companies
15.3 North America Antibody Drug Conjugates Market, Segmentation By Linker Type, Historic And Forecast, 2018 - 2023, 2028F, 2033F, Value ($ Million)
15.4 North America Antibody Drug Conjugates Market, Segmentation By Application, Historic And Forecast, 2018 - 2023, 2028F, 2033F, Value ($ Million)
15.5 North America Antibody Drug Conjugates Market, Segmentation By End User, Historic And Forecast, 2018 - 2023, 2028F, 2033F, Value ($ Million)
15.6 North America Antibody Drug Conjugates Market: Country Analysis
15.7 USA Market
15.8 Summary
15.9 Market Overview
- 15.9.10 Country Information
- 15.9.2 Market Information
- 15.9.3 Background Information
- 15.9.4 Government Initiatives
- 15.9.5 Regulations
- 15.9.6 Regulatory Bodies
- 15.9.7 Major Associations
- 15.9.8 Taxes Levied
- 15.9.9 Corporate Tax Structure
- 15.9.10 Investments
- 15.9.11 Major Companies
15.10 USA Antibody Drug Conjugates Market, Segmentation By Linker Type, Historic And Forecast, 2018 - 2023, 2028F, 2033F, Value ($ Million)
15.11 USA Antibody Drug Conjugates Market, Segmentation By Application, Historic And Forecast, 2018 - 2023, 2028F, 2033F, Value ($ Million)
15.12 USA Antibody Drug Conjugates Market, Segmentation By End User, Historic And Forecast, 2018 - 2023, 2028F, 2033F, Value ($ Million)
15.13 Canada Market
15.14 Canada Antibody Drug Conjugates Market, Segmentation By Linker Type, Historic And Forecast, 2018 - 2023, 2028F, 2033F, Value ($ Million)
15.15 Canada Antibody Drug Conjugates Market, Segmentation By Application, Historic And Forecast, 2018 - 2023, 2028F, 2033F, Value ($ Million)
15.16 Canada Antibody Drug Conjugates Market, Segmentation By End User, Historic And Forecast, 2018 - 2023, 2028F, 2033F, Value ($ Million)

16 South America Market

16.1 Summary
16.2 Market Overview
- 16.2.1 Region Information
- 16.2.2 Market Information
- 16.2.3 Background Information
- 16.2.4 Government Initiatives
- 16.2.5 Regulations
- 16.2.6 Regulatory Bodies
- 16.2.7 Major Associations
- 16.2.8 Taxes Levied
- 16.2.9 Corporate Tax Structure
- 16.2.10 Major Companies
16.3 South America Antibody Drug Conjugates Market, Segmentation By Linker Type, Historic And Forecast, 2018 - 2023, 2028F, 2033F, Value ($ Million)
16.4 South America Antibody Drug Conjugates Market, Segmentation By Application, Historic And Forecast, 2018 - 2023, 2028F, 2033F, Value ($ Million)
16.5 South America Antibody Drug Conjugates Market, Segmentation By End User, Historic And Forecast, 2018 - 2023, 2028F, 2033F, Value ($ Million)
16.6 South America Antibody Drug Conjugates Market: Country Analysis
16.7 Brazil Market
16.8 Brazil Antibody Drug Conjugates Market, Segmentation By Linker Type, Historic And Forecast, 2018 - 2023, 2028F, 2033F, Value ($ Million)
16.9 Brazil Antibody Drug Conjugates Market, Segmentation By Application, Historic And Forecast, 2018 - 2023, 2028F, 2033F, Value ($ Million)
16.10 Brazil Antibody Drug Conjugates Market, Segmentation By End User, Historic And Forecast, 2018 - 2023, 2028F, 2033F, Value ($ Million)

17 Middle East Market

17.1 Summary
17.2 Market Overview
- 17.2.1 Region Information
- 17.2.2 Market Information
- 17.2.3 Background Information
- 17.2.4 Government Initiatives
- 17.2.5 Regulations
- 17.2.6 Regulatory Bodies
- 17.2.7 Major Associations
- 17.2.8 Taxes Levied
- 17.2.9 Corporate Tax Structure
- 17.2.10 Major Companies
17.3 Middle East Antibody Drug Conjugates Market, Segmentation By Linker Type, Historic And Forecast, 2018 - 2023, 2028F, 2033F, Value ($ Million)
17.4 Middle East Antibody Drug Conjugates Market, Segmentation By Application, Historic And Forecast, 2018 - 2023, 2028F, 2033F, Value ($ Million)
17.5 Middle East Antibody Drug Conjugates Market, Segmentation By End User, Historic And Forecast, 2018 - 2023, 2028F, 2033F, Value ($ Million)

18 Africa Market

18.1 Summary
18.2 Market Overview
- 18.2.1 Region Information
- 18.2.2 Market Information
- 18.2.3 Background Information
- 18.2.4 Government Initiatives
- 18.2.5 Regulations
- 18.2.6 Regulatory Bodies
- 18.2.7 Major Associations
- 18.2.8 Taxes Levied
- 18.2.9 Corporate Tax Structure
- 18.2.10 Major Companies
18.3 Africa Antibody Drug Conjugates Market, Segmentation By Linker Type, Historic And Forecast, 2018 - 2023, 2028F, 2033F, Value ($ Million)
18.4 Africa Antibody Drug Conjugates Market, Segmentation By Application, Historic And Forecast, 2018 - 2023, 2028F, 2033F, Value ($ Million)
18.5 Africa Antibody Drug Conjugates Market, Segmentation By End User, Historic And Forecast, 2018 - 2023, 2028F, 2033F, Value ($ Million)

19 Competitive Landscape and Company Profiles

19.1 Company Profiles
19.1 F. Hoffman-La Roche Ltd
- 19.1.1 Company Overview
- 19.1.2 Products And Services
- 19.1.3 Business Strategy
- 19.1.4 Financial Overview
19.2 Daiichi Sankyo Company Limited
- 19.2.1 Company Overview
- 19.2.2 Products And Services
- 19.2.3 Business Strategy
- 19.2.4 Financial Overview
19.3 Seagen Inc
- 19.3.1 Company Overview
- 19.3.2 Products And Services
- 19.3.3 Business Strategy
- 19.3.4 Financial Overview
19.4 Gilead Sciences Inc
- 19.4.1 Company Overview
- 19.4.2 Products And Services
- 19.4.3 Business Strategy
- 19.4.4 Financial Overview
19.5 Genmab A/S
- 19.5.1 Company Overview
- 19.5.2 Products And Services
- 19.5.3 Business Strategy
- 19.5.4 Financial Overview

20 Other Major And Innovative Companies

20.1 Pfizer
- 20.1.1 Company Overview
- 20.1.2 Products And Services
20.2 GlaxoSmithKline plc
- 20.2.1 Company Overview
- 20.2.2 Products And Services
20.3 ADC Therapeutics SA
- 20.3.1 Company Overview
- 20.3.2 Products And Services
20.4 AstraZeneca plc
- 20.4.1 Company Overview
- 20.4.2 Products And Services
20.5 RemeGen
- 20.5.1 Company Overview
- 20.5.2 Products And Services
20.6 Astellas Pharma Inc.
- 20.6.1 Company Overview
- 20.6.2 Products And Services
20.7 ImmunoGen Inc.
- 20.7.1 Company Overview
- 20.7.2 Products And Services
20.8 Rakuten Medical
- 20.8.1 Company Overview
- 20.8.2 Products And Services
20.9 Takeda Pharmaceutical Company Limited
- 20.9.1 Company Overview
- 20.9.2 Products And Services
20.10 AbbVie Inc.
- 20.10.1 Company Overview
- 20.10.2 Products And Services
20.11 Mersana Therapeutics Inc.
- 20.11.1 Company Overview
- 20.11.2 Products And Services
20.12 Merck Co. & KGaA
- 20.12.1 Company Overview
- 20.12.2 Products And Services
20.13 Bristol Myers Squibb Co.
- 20.13.1 Company Overview
- 20.13.2 Products And Services
20.14 Novo Nordisk A/S
- 20.14.1 Company Overview
- 20.14.2 Products And Services
20.15 Bayer AG
- 20.15.1 Company Overview
- 20.15.2 Products And Services

21 Competitive Benchmarking

22 Competitive Dashboard

23 Key Mergers And Acquisitions

23.1 Genmab A/S Acquired ProfoundBio Inc
23.2 Johnson & Johnson (J&J) Acquired Ambrx Biopharma Inc
23.3 AbbVie Acquired ImmunoGen, Inc
23.4 Pfizer Inc Acquired Seagen Inc

24 Opportunities And Strategies

24.1 Global Antibody Drug Conjugates Market In 2028 - Countries Offering Most New Opportunities
24.2 Global Antibody Drug Conjugates Market In 2028 - Segments Offering Most New Opportunities
24.3 Global Antibody Drug Conjugates Market In 2028 - Growth Strategies
- 24.3.1 Market Trend Based Strategies
- 24.3.2 Competitor Strategies

25 Antibody Drug Conjugates Market, Conclusions And Recommendations

25.1 Conclusions
25.2 Recommendations
- 25.2.1 Product
- 25.2.2 Place
- 25.2.3 Price
- 25.2.4 Promotion
- 25.2.5 People

26 Appendix

26.1 Geographies Covered
26.2 Market Data Sources
26.3 Research Methodology
26.4 Currencies
26.5 The Business Research Company
26.6 Copyright and Disclaimer